To access this material please log in or register

Register Authorize

Use of carvedilol in treatment of arterial hypertension

Parnes E. Ya.

Keywords: hyperpiesis, beta-adrenergic blocker agents, carvedilol

DOI: 10.18087/rhj.2012.5.1713

Results of the meta-analyses assessing efficiency of beta-blockers in treatment of noncomplicated AH, evidence their lesser efficiency than that of ACE inhibitors, angiotensin II receptor blockers, calcium-channel blockers and diuretics. The overwhelming majority of the studies were carried out with use atenolol and metoprolol tartrate, though. Carvedilol, even being a beta-blocker, does not has many adverse properties of drugs of this group: it does not cause increase of peripheral resistance, does not raise central aortic pressure, does not promote increase of blood glucose level, does not raise thyroglobulin level and total cholesterol in blood, does not cause expressed negative chronotropic effect, which is why is easier tolerated, including by elderly patients. On the other hand, carvedilol has many positive effects, which are not typical for previous generations beta-blockers. Among them: positive effects on endothelium dysfunction, improving of central haemodynamics, LV hypertrophy regression, reducing of vascular wall rigidity, coronary reserve increase, cardio- and nephroprotective action, positive impact on insulin resistance, antioxidative, anti-inflammatory and antiproliferative effects., Taking into account absence of the influence on carbohydrate and lipid exchanges, Carvedilol can be used in persons with metabolic syndrome, DM type 2, and in patients with peripheral artery diseases.
  1. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43 (1):10–17.
  2. Sarafidis PA, Lasaridis A, Gousopoulos S et al. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum Hypertens. 2004;18 (9):623–629.
  3. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10 (2):130–139.
  4. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335 (8692):765–774.
  5. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks.US population data. Arch Intern Med. 1993;153 (5):598–615.
  6. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335 (8693):827–838.
  7. MacMahon S, Rodgers A, Neal B, Chalmers J. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension. 1997;29 (2):537–538.
  8. Khan N, McAlister FA. Re-examining the efficacy of beta-blo­ckers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174 (12):1737–1742.
  9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25 (6):1105–1187.
  10. Chobanian AN, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289 (19):2560–2572.
  11. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364 (9446):1684–1689.
  12. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366 (9496):1545–1553.
  13. Mancia G, De BG, Mayosi BM et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002003.
  14. Ram CV. Beta-blockers in hypertension. Am J Cardiol. 2010;106 (12):1819–1825.
  15. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004‑BHS IV. J Hum Hypertens. 2004;18 (3):139–185.
  16. Wiysonge CSU, Bradley HA, Mayosi BM et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002003. DOI: 10.1002 / 14651858. CD002003.pub2
  17. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens. 1988;1 (1):91–96.
  18. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007;25 (1):249–252.
  19. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99 (7):431–436.
  20. Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006;2 (3):303–308.
  21. Opie L, Yusuf S. Beta-blocking agents. In: Opie LH, Gersh B, editors. Drugs for the Heart 6. – Philadelphia, Pensylvania: W. B. Saunders Company; 2005. pp. 1–32.
  22. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993;45 (2):232–258.
  23. Yoshikawa T, Port JD, Asano K et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17 (Suppl B): 8–16.
  24. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26 (5):335–346.
  25. Frishman WH. Carvedilol. N Engl J Med. 1998;339 (24):1759–1765.
  26. Messerli FH, Grossman E. beta-Blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93 (9A): 7B-12B.
  27. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart. 2000;84 (6):615–961.
  28. Diehm C. Antihypertensive therapy in arterial occlusive disease. Vasa Suppl. 1991;33:71–4.
  29. Nagakawa Y, Akedo Y, Kaku S, Orimo H. Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension. Eur J Clin Pharmacol. 1990;38 (Suppl 2):S115–119.
  30. Chen JW, Lin FY, Chen YH et al. Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression, and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004;24 (11):2075–2081.
  31. Jeong I, Choi BH, Yoon SH, Hahn SJ. Carvedilol blocks the cloned cardiac Kv1.5 channels in a β-adrenergic receptor-independent manner. Biochem Pharmacol. 2012;83 (4):497–505.
  32. Tamargo J, Caballero R, Gómez R, Delpón E. I (Kur) / Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs. 2009;18 (4):399–416.
  33. Knobloch K, Brendel J, Rosenstein B et al. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. Med Sci Monit. 2004 Jul;10 (7):BR221–228.
  34. Vailati Mdo C, Rocha NS, Matsubara LS et al. Protective effects of carvedilol on systemic vascular damage induced by angiotensin II: organ-specific effects independent of antihypertensive effects. Med Sci Monit. 2010;16 (1):BR6–10.
  35. Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292 (18):2227–2236.
  36. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006;21 (9):2366–2374.
  37. Henderson LS, Tenero DM, Baidoo CA et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol. 2006;98 (7A): 17L-26L.
  38. Weber MA, Bakris GL, Tarka EA et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8 (12):840–849.
  39. Бабкин А. П., Гладких В. В., Першуков И. В., Гулая Г. И. Сравни­тельная эффективность антигипертензивной терапии у больных с различной солечувствительностью артериальной гипертензии. Кардиология. 2010;50 (10):35–38.
  40. COREG СR Versus TOPROL–XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension. Available at: http://clinicaltrials.gov / ct2 / show / results / NCT00273052
  41. Mori Y, Nishikawa Y, Iizuka T et al. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. Drugs R D. 2011;11 (2):171–190.
  42. Aronow WS, Fleg JL, Pepine CJ et al. ACCF / AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am CollCardiol. 2011;57 (20):2037–2114.
  43. LAAS (Losartan Anti-Atherosclerosis Study) (0954-330) Study NCT00496834. Available at: http://clinicaltrials.gov / ct2 / show / results / NCT00496834
  44. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113 (9):1213–1225.
  45. Shah NK, Smith SM, Nichols WW et al. Carvedilol reduces aortic wave reflection and improves left ventricular / vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich). 2011;13 (12):917–924.
  46. Polónia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator pro­perties or with angiotensin receptor blockers.Blood Press Monit. 2010;15 (5):235–239.
  47. Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4 (1):23–30.
  48. Thuillez C. Endothelial dysfunction: role of vasodilating betablo­ckers in hypertension and chronic heart failure. Ann Cardiol Angeiol (Paris). 2010;59 (2):86–92.
  49. Bank AJ, Kelly AS, Thelen AM et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20 (7):777–783.
  50. Giugliano D., Harfella R., Acamporo R. et al. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 1998;21 (4):402–409.
  51. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). 2010 г. Доступно на: http: gipertonik.ru / files / recommendation-ag-2010.pdf
  52. Soininen K, Gerlin-Piira L, Suihkonen J et al. A study of the effects of lisinopril when used in addition to atenolol. J Hum Hypertens. 1992;6 (4):321–324.
  53. Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure. Available at: http://clinicaltrials.gov / ct2 / show / results / NCT00624065
  54. Bakris GL, Iyengar M, Lukas MA et al. Effect of combining extended-release сarvedilol and lisinopril in hypertension: results of the COSMOS study. J ClinHypertens (Greenwich). 2010;12 (9):678–686.
  55. Messerli FH, Aristizabal D, Soria F. Reduction of left ventricular hypertrophy: how beneficial? Am Heart J. 1993;125 (5 Pt 2):1520–1524.
  56. Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci. 1999;317 (3):168–175.
  57. Miller AB, Reichek N, St John Sutton M et al. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010;4 (6):302–310.
  58. Fleischmann EH, Schmieder RE. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep. 2002;4 (6):474–478.
  59. Verdecchia P, Angeli F, Pittavini L et al. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J. 2004;5 (7):505–510.
  60. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl. 2005;23: S27‑S33.
  61. Schulman SP, Weiss JL, Becker LC et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med. 1990;322 (19):1350–1356.
  62. Dahlöf B, Devereux RB, Kjeldsen SE et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003.
  63. Galzerano D, Tammaro P, del Viscovo L et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens. 2005;18 (12 Pt 1):1563–1569.
  64. Grimm D, Huber M, Jabusch HC et al. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. J Mol Cell Cardiol. 2001;33 (3):487–501.
  65. Chen WQ, Cai H, Zhang C, Ji XP, Zhang Y. Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats? Hypertens Res. 2010;33 (10):1071–1081.
  66. Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press. 2010;19 (1):40–47.
  67. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26 (3):615–629.
  68. Carella AM, Antonucci G, Conte M et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev. 2010;6 (4):215–221.
  69. Fonseca V, Sharma PP, Shah M, Deedwania P. Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension. Curr Med Res Opin. 2011;27 (4):799–807.
  70. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized controlled trial. Ann Intern Med. 1997;126 (12):955–959.
  71. Iizuka T, Nishikawa Y, Mori Y et al. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a long-term special survey. Drugs R D. 2011;11 (2):191–205.
  72. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362 (9377):7–13.
  73. Олейников В. Э., Матросова И. Б., Елисеева И. В. и др. Органо­протективные эффекты карведилола у больных артериальной гипертонией в сочетании с метаболическим синдромом. Кардиология 2009;49 (11):27–32.
  74. Лукина Ю. В., Марцевич С. Ю., Деев А. Д., Шальнова С. А. Срав­ни­тельное контролируемое исследование антигипертензивной эффективности и безопасности терапии карведилолом у больных артериальной гипертонией и ожирением или сахарным диабетом 2‑го типа (по результатам многоцентрового исследования АККОРД). Рациональная Фармакотерапия в Кардиологии. 2009;3:19–24.
  75. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009;11 (3):234–238.
  76. Wehland M, Grosse J, Simonsen U et al. The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease. Curr Vasc Pharmacol. 2012;10 (3):378–390.
  77. Pedersen ME, Cockcroft JR. What is the role, if any, for beta-blo­ckers as initial therapy for uncomplicated hypertension? Curr Opin Cardiol. 2009;24 (4):325–332.
  78. Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010 Nov;11 (16):2599–2607.
  79. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010;105 (10):1433–1438.
  80. Basile JN. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Am J Med. 2010;123 (7 Suppl 1):S9–15.
  81. Black HR, Greenberg BH, Weber MA. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. Am J Med. 2010;123 (11):S2.
Parnes E. Ya. Use of carvedilol in treatment of arterial hypertension. Russian Heart Journal. 2012;11(5):309-317.

To access this material please log in or register

Register Authorize
Ru En